Infectious Diseases Department, University Hospital of Caracas, Caracas, Venezuela.
"Dr. José Antonio O'Daly" Anatomopathological Institute, Central University of Venezuela, Caracas, Venezuela.
BMC Infect Dis. 2021 Nov 4;21(1):1134. doi: 10.1186/s12879-021-06819-9.
Amoebiasis is a parasitic disease caused by Entamoeba histolytica, which affects people living in low- and middle-income countries and has intestinal and extraintestinal manifestations. To date, knowledge on coronavirus disease 2019 (COVID-19) coinfection with enteric parasites is limited, and E. histolytica coinfection has not been previously described. Here we present the case of a patient with COVID-19 who, during hospitalisation, presented a clinical picture consistent with an amoebic liver abscess (ALA).
A 54-year-old man, admitted as a suspected case of COVID-19, presented to our hospital with dyspnoea, malaise, fever and hypoxaemia. A nasopharyngeal swab was positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse-transcription polymerase chain reaction. After 7 days, he developed diarrhoea, choluria and dysentery. An abdominal ultrasound showed a lesion compatible with a liver abscess; stool examination revealed E. histolytica trophozoites, and additional serology for E. histolytica was positive. After 12 days of treatment with metronidazole, ceftazidime and nitazoxanide, the patient reported acute abdominal pain, and an ultrasound examination revealed free liquid in the abdominal cavity. An emergency exploratory laparotomy was performed, finding 3000 mL of a thick fluid described as "anchovy paste". Computed tomography scan revealed a second abscess. He ended up receiving 21 days of antibiotic treatment and was discharged with satisfactory improvement.
Here we present, to the best of our knowledge, the first report of ALA and COVID-19 co-presenting. Based on their pathophysiological similarities, coinfection with SARS-CoV-2 and E. histolytica could change the patient's clinical course; however, larger studies are needed to fully understand the interaction between these pathogens.
阿米巴病是由溶组织内阿米巴引起的寄生虫病,影响生活在中低收入国家的人群,具有肠道和肠道外表现。迄今为止,关于 2019 年冠状病毒病(COVID-19)与肠道寄生虫合并感染的知识有限,尚未描述溶组织内阿米巴合并感染。在此,我们报告了一例 COVID-19 患者的病例,该患者在住院期间出现了与阿米巴性肝脓肿(ALA)一致的临床表现。
一名 54 岁男性,因疑似 COVID-19 入院,因呼吸困难、不适、发热和低氧血症就诊于我院。鼻咽拭子经逆转录聚合酶链反应检测出严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)阳性。7 天后,他出现腹泻、胆尿和痢疾。腹部超声显示病变符合肝脓肿;粪便检查发现溶组织内阿米巴滋养体,且额外的溶组织内阿米巴血清学检查呈阳性。在接受甲硝唑、头孢他啶和硝唑尼特治疗 12 天后,患者出现急性腹痛,超声检查显示腹腔内有游离液体。行急诊剖腹探查术,发现 3000 毫升浓稠液体,描述为“凤尾鱼酱”。计算机断层扫描显示第二个脓肿。他最终接受了 21 天的抗生素治疗,出院时病情明显改善。
据我们所知,这是首次报告 ALA 与 COVID-19 同时出现。基于它们的病理生理学相似性,COVID-19 与溶组织内阿米巴合并感染可能会改变患者的临床病程;然而,需要更大的研究来充分了解这些病原体之间的相互作用。